You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 20, 2024

Bausch Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bausch
International Patents:775
US Patents:121
Tradenames:155
Ingredients:122
NDAs:176
Patent Litigation for Bausch: See patent lawsuits for Bausch

Drugs and US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206046-001 Jul 26, 2017 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bausch Lomb Ireland FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE benoxinate hydrochloride; fluorescein sodium SOLUTION/DROPS;OPHTHALMIC 211039-001 Mar 9, 2020 RX Yes Yes 10,842,872 ⤷  Try a Trial ⤷  Try a Trial
Bausch DUOBRII halobetasol propionate; tazarotene LOTION;TOPICAL 209354-001 Apr 25, 2019 RX Yes Yes 10,478,502 ⤷  Try a Trial Y ⤷  Try a Trial
Bausch CABTREO adapalene; benzoyl peroxide; clindamycin phosphate GEL;TOPICAL 216632-001 Oct 20, 2023 RX Yes Yes 10,220,049 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch VANOS fluocinonide CREAM;TOPICAL 021758-001 Feb 11, 2005 7,220,424 ⤷  Try a Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 6,923,984 ⤷  Try a Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 7,108,866 ⤷  Try a Trial
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 5,908,838 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Lotion 0.1% ➤ Subscribe 2016-08-31
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Extended-release Tablet 55 mg and 80 mg ➤ Subscribe 2010-12-02
➤ Subscribe Gel 1.2%/2.5% ➤ Subscribe 2012-12-20
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17
➤ Subscribe Topical Solution 10% ➤ Subscribe 2018-06-06
➤ Subscribe Cream 0.10% ➤ Subscribe 2008-01-31
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Extended-release Tablets 65 mg and 115 mg ➤ Subscribe 2009-11-19
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablet 105 rng ➤ Subscribe 2010-12-28
➤ Subscribe Gel 1.2%/3.75% ➤ Subscribe 2015-09-30
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09
➤ Subscribe Gel 1.2%/0.025% ➤ Subscribe 2010-12-17

Supplementary Protection Certificates for Bausch Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0427680 SZ 12/2003 Austria ⤷  Try a Trial PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE
0656775 28/2000 Austria ⤷  Try a Trial PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
0186405 SPC/GB00/021 United Kingdom ⤷  Try a Trial PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
0427680 12/2003 Austria ⤷  Try a Trial PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE; NAT. REGISTRATION NO/DATE: 1-24689 20020917; FIRST REGISTRATION: DK 21034 20020315
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.